Bayer Corp has licensed commercial rights in the USA to Viadur(leuprolide acetate implant), a once-yearly implant for the palliative treatment of advanced prostate cancer developed by Alza using its proprietary DUROS drug delivery technology. Viadur, which was approved by the US Food and Drug Administration last month, is the first and only product to provide continuous, 12-month testosterone suppression with a single treatment (Marketletter March 13).
Under the terms of the royalty and milestone-bearing license, Bayer has marketing rights to Viadur in the USA through 2015. Alza will also receive manufacturing, patent and trademark payments on a quarterly basis through the third quarter of 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze